Ecuador brings new national pharmacovigilance regulations into force
By Robalino
Ecuador has brought into force new technical health regulations governing the operation of its National Pharmacovigilance System, establishing obligations for the various stakeholders involved in detecting, reporting, assessing and preventing risks associated with the use of medicinal products.
The regulation, known as the Substitute Technical Health Regulation for the Operation of the National Pharmacovigilance System, was approved through Resolution ARCSA-DE-2025-052-DASP and entered into force on November 4, 2026.
Compliance is mandatory for public and private entities participating in the system. Its scope includes marketing authorization holders, pharmaceutical establishments, healthcare facilities and healthcare professionals, among other stakeholders.
The regulation applies to medicines, biological products for human use, processed natural medicinal products and homeopathic products. It also covers products subject to its provisions that enter the country through exceptional importation, donation or recognition procedures.
One of the relevant technical aspects is the introduction of deadlines for implementing international coding standards. Pharmaceutical establishments and marketing authorization holders must adopt MedDRA terminology by August 4, 2027, to code clinical manifestations, diseases and abnormal laboratory findings. They must also implement the WHODrug dictionary for coding medicines and vaccines, in accordance with the guidelines issued by the National Agency for Health Regulation, Control and Surveillance (ARCSA).
The authority clarified that this specific deadline does not postpone the entry into force of the remaining provisions. Accordingly, the general obligations established under the regulation have been enforceable since November 4, 2026.
Implementation of the new framework requires affected stakeholders to review their internal procedures, adverse event reporting mechanisms, records and pharmacovigilance system documentation, as well as the responsibilities assigned to the personnel in charge.
The regulatory update forms part of broader efforts to strengthen health surveillance and risk management mechanisms for medicinal products marketed in Ecuador.
